PubMed Journals Articles About "Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients" RSS

03:15 EST 20th January 2020 | BioPortfolio

Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients articles that have been published worldwide.

More Information about "Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients" on BioPortfolio

We have published hundreds of Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients news stories on BioPortfolio along with dozens of Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients Clinical Trials and PubMed Articles about Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients Companies in our database. You can also find out about relevant Effect Of 25-OH-vitamin D3 On The Liver Transplant Recipients Drugs and Medications on this site too.

Showing "Effect vitamin Liver Transplant Recipients" PubMed Articles 1–25 of 27,000+

Vitamin D deficiency is common in kidney transplant recipients, but is not associated with infections after transplantation.

The relevance of vitamin D for infections after kidney transplantation is poorly defined. 25-OH vitamin D (25-OHD) levels of 135 kidney transplant recipients, enrolled in the Swiss Transplant Cohort Study, were determined peri-transplant and 6 months post-transplant. Logistic regression was used to address associations of 25-OHD and overall infections and bacterial infections, respectively. For the first 6 months post-transplant, 25-OHD peri-transplant, and for the second period (after 6 to 30 months post-t...

Tuberculosis treatment with a three drug rifamycin-free regimen in liver transplant recipients.

Active tuberculosis (TB) is a severe and potentially fatal complication of liver transplantation (1). The management of TB in liver transplant (LT) recipients is challenging not only because of the severity of this infection, but because first-line TB treatment is associated with significant hepatotoxicity and drug interactions.

Projected 20- and 30-Year Outcomes for Pediatric Liver Transplant Recipients in the United States.

Observed long-term outcomes no longer reflect the survival trajectory facing pediatric liver transplant (LT) recipients today. We aimed to use national registry data and parametric models to project 20- and 30-year post-transplant outcomes for recently transplanted pediatric LT recipients.

Pre- and Peri-Operative Factors Associated with Chronic Critical Illness in Liver Transplant Recipients.

Chronic critical illness (CCI) is a new and increasing entity that accounts for substantial cost despite its low incidence. We hypothesized that patients with end-stage liver failure undergoing liver transplant would be at high risk for developing CCI. With limited liver donors it is essential to understand pre- and peritransplant predictors of CCI. To accomplish this we performed a retrospective cohort study at a large academic transplant center of all adult liver transplant patients from 2011 to 2017. We...

Hepatitis E seroprevalence and associated risk factors in Croatian liver transplant recipients.

Solid-organ transplant recipients are at risk of hepatitis E virus (HEV) infection. We analyzed the seroprevalence/risk factors of HEV in Croatian liver transplant recipients.

Macrosteatotic Allografts and Obese Recipients Have Nearly Equal Negative Impact on Liver Transplant Survival.

Our aim was to evaluate liver transplant outcomes involving donors with high macrosteatosis grafts in the obese modern liver transplant recipient population.

Mind the Gap: Statin Underutilization and Impact on Mortality in Liver Transplant Recipients.

Liver transplant (LT) recipients are at a substantially increased risk of cardiovascular disease compared due to accelerated development and progression of hypertension, diabetes, obesity and dyslipidemia. As a result, cardiovascular disease is a leading cause of morbidity and mortality post-LT. This is in spite of aggressive pre-transplant evaluation for prevalent cardiovascular disease, in particular coronary artery disease (CAD), and exclusion of very high-risk patients from LT. However the commonest cau...

Novel educational and goal-setting tool to improve knowledge of chronic kidney disease among liver transplant recipients: A pilot study.

Liver transplant (LT) recipients have limited understanding of post-transplant chronic kidney disease (CKD) despite an excellent pre-existing framework of transplant care. This pilot study examined the efficacy and feasibility of a tailored educational and goal-setting tool in improving CKD knowledge among LT recipients with early-stage CKD.

Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection - a multinational survey.

There is no consensus on the optimal management of immunosuppression during bacterial infections among solid organ transplant recipients.

Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene polymorphisms in liver transplant donors and impact on acute cellular liver transplant rejection.

The PTPN22 gene encodes the lymphoid protein tyrosine phosphatase involved in regulation the immune response. The single nucleotide polymorphisms (SNPs) rs1217388, rs1310182, rs2476601, and rs2488457 are located within the PTPN22 gene. We investigated whether these SNPs in liver transplant donors are associated with acute cellular rejection in the recipients. The SNPs were analyzed in donors (n = 104) of recipients who did not develop an acute cellular rejection and in donors (n = 53) of corresponding r...

Efficacy and safety of everolimus treatment on liver transplant recipients: a meta-analysis.

Everolimus is an effective immunosuppressant in organ transplantation without impaired renal function. The present study aimed to evaluate the efficacy and safety of everolimus therapy in liver transplant recipients.

PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.

Immune checkpoint inhibitors represent a newly established standard of care in patients with refractory metastatic colorectal cancer with mismatch repair deficiency and microsatellite instability. However, the use of immunotherapy is unclear in recipients of liver transplants with or without concurrent liver function abnormalities. Clinical trials investigating immunotherapy have mostly excluded liver transplant recipients and patients with abnormal liver function. This report presents the first case, to ou...

Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients.

Tacrolimus is utilized as maintenance immunosuppression in solid organ transplant (SOT). Current literature has reported conflicting conversion ratios when transitioning between oral and sublingual tacrolimus and the exact conversion ratio has not been fully established in SOT. The purpose of this study was to determine the conversion ratios between oral and sublingual tacrolimus needed to achieve equivalent whole blood concentrations in heart, kidney, liver, and lung transplant recipients. A retrospective,...

Toxoplasma infection in kidney donors and transplant recipients from Western Mexico: A one-year follow-up.

Solid-organ transplant recipients are highly susceptible to Toxoplasma gondii infection. We aimed to describe the 12-month follow-up risk of seroconversion in renal transplant recipients.

Obesity and Liver Disease: The New Era of Liver Transplantation.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum that ranges from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. NAFLD is now the most common chronic liver disease in many developed countries. The latest Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients (OPTN/SRTR) annual liver transplant report showed that hepatitis C (HCV) infection was no longer the most common indication for liver transplant; instead "other/unknown etiology" beca...

Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors.

Post-liver transplant (LT) metabolic syndrome (PTMS) and cardiovascular (CVS) mortality are becoming increasingly prevalent following sustained improvements in post-LT survival. We investigated the prevalence and predictors of PTMS and CVS complications in a cohort of consecutive LT recipients.

Early Liver Transplantation in Acute Alcoholic Hepatitis.

Alcohol-related liver disease (ALD) is currently the leading indication for liver transplantation in the United States. Among patients with ALD, those with acute alcoholic hepatitis who do not respond to medical treatment have a 6-month mortality of 70% without transplantation. Despite the high mortality, the majority of patients will not be eligible for transplant, given that most centers follow the 6-month abstinence rule. A handful of centers in Europe and the United States perform early liver transplant...

Excess Stroke Deaths in Kidney Transplant Recipients: A Retrospective Population-based Cohort Study Using Data Linkage.

Kidney transplant recipients are thought to experience a high risk of stroke, however little data exists. We aimed to compare the stroke deaths in kidney transplant recipients with the general population and identify risk factors for stroke death in kidney transplant recipients.

Acute Cellular Rejection in hepatitis C recipients Following Liver Transplantation in the Era of Direct Acting Antivirals: Chronological Analysis of UNOS Database.

Interferon (IFN) treatment for liver transplant (LT) recipients with hepatitis C virus (HCV) increases acute cellular rejection (ACR), and worsens graft and patient survival. It is unknown if direct acting antivirals (DAA) affect rejection rates or post-transplant survival.

Health-Related Quality of Life and Cognitive Functioning in Pediatric Liver Transplant Recipients.

Examine the change in health-related quality of life (HRQOL) and cognitive functioning from early childhood to adolescence in pediatric liver transplant (LT) recipients. Study design Patients were recruited from 8 North American centers through the Studies of Pediatric Liver Transplant consortium. 79 participants, ages 11-18 years, previously tested at age 5-6 years in the Functional Outcomes Group study were identified as surviving most recent LT by 2 years and in stable medical follow-up. The PedsQLTM 4.0...

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.

This multicenter trial compared immediate-release tacrolimus (IR-T) versus prolonged-release tacrolimus (PR-T) in de novo kidney-, liver-, and heart-transplant recipients aged

Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation.

The development of multiple highly effective and safe direct-acting antivirals to treat hepatitis C virus (HCV) has resulted in greater ease and confidence in managing HCV infection in transplant recipients that in turn, has impacted the solid organ transplant community as well. In the United States, the opioid epidemic has increased the number of overdose deaths with a concomitant increase in younger HCV viremic donors after brain death being identified. At the same time, a decrease in HCV viremic transpla...

Clinical Course of Renal Disease in Recipients of Liver Transplant Who Required Peritransplant Dialysis.

Renal dysfunction is a common complication and one of the factors that affects the outcomes of liver transplantation (LT). The aim of this study was to review the clinical course of recipients of LT who needed peritransplant dialysis at our center.

Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria, Australia.

Improved prognosis of post-transplant melanomas may be due to early diagnosis due to screening of organ transplant recipients in a dedicated transplant dermatology clinic. The benign to malignant ratio of pigmented lesions in our cohort was 16:1.

The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients.

Sirolimus has been shown to ameliorate steroid-resistant rejection and induce long-term immune tolerance among liver transplant patients. However, the detailed mechanism of how Sirolimus achieve these advantages is still lacking. This study attempts to reveal some possible mechanisms by investigating regulatory B cells (Bregs), regulatory T cells (Tregs) and some cytokines in liver transplant recipients whose Tacrolimus was partially converted to Sirolimus. The results showed that CD19CD24CD38Bregs and CD4C...

Quick Search